A new generic treatment for multiple types of cancer一种治疗多种类型癌症的新的通用疗法 由日本理化学研究所先锋研究集群(CPR)的Katsunori Tanaka和理化学研究所西那加速器科学中心(RNC)的Hiromitsu Haba领导的研究人员已经开发出一种新技术,有可能通用于治疗几种癌症,而且比目前可用的方法有更少的负面效应。6月...
The article reports on the peripheral-acting mu opioid receptor antagonists, a new class of drugs for cancer patients and other advanced illness patients. The first drug to be approved in this c...
A week after the diagnosis, El-Afandi underwent surgery to remove the tumor. This is standard for glioblastoma treatment, but even after surgery, there's usually cancerous cells left behind because of the way the tumors grow in the brain. That's part of why the mortality rate for glioblasto...
It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation, the FDA said on Friday. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test. "This class of drugs has been used to...
9, 465–472; 2023). More than 50 years after the US declaration of a war on cancer, many hoped that the disease would be closer to defeat than these statistics suggest. People diagnosed with cancer today often still contend with the dismal side effects and highly uncertain outcomes ...
New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer In the United States, cancer of the pancreas accou Melstrom,Laleh,G.,... - 《Oncology》 被引量: 5发表: 2017年 Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic ca...
Cancer cell during cell division. Credit: National Institutes of Health A new treatment for advanced urothelial cancer was effective with tolerable side effects in an international, multi-center phase 2 clinical trial led by investigators at Weill Cornell Medicine and NewYork-Presbyterian. ...
In a survey looking at 115 countries, the WHO also found a majority of nations don't spend enough on cancer care and treatment. "This is not the time to turn away. It's the time to double down and make those investments in cancer prevention and control," said Dr. Andre IIbawi,...
CHICAGO, June 4 (Xinhua) -- A combination of two existing prostate cancer therapies could extend lives of men with advanced, high-risk prostate cancer, a study showed. The addition of Zytiga to androgen-deprivation therapy can "significantly" increase overall survival in men with newly diagnosed...
is exciting. There is hope for a breakthrough therapy in the future, and it has provided a solid foundation for the rapid advancement into Phase I/II. Sincere wishes for further progress and breakthroughs in this project, bringing better data and ou...